2′-Deoxyriboguanylurea, the primary breakdown product of 5-aza-2′-deoxyribocytidine, is a mutagen, an epimutagen, an inhibitor of DNA methyltransferases and an inducer of 5-azacytidine-type fragile sites

Nucleic Acids Research

Volumn 40, Issue 19, 2012, Pages 9788-9801

  Lamparska, Katarzyna ^a   Clark, Jarrod ^a   Babilonia, Gail ^a   Bedell, Victoria ^b   Yip, Wesley ^a   Smith, Steven S ^a  

^a Beckman Research Institute   (United States)

^b CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 DEOXYRIBOAGUANYLUREA; 5 AZA 2' DEOXYRIBOCYTIDINE; ALANINE; AZACITIDINE; CLASTOGEN; CYTOSINE; DNA METHYLTRANSFERASE; DNA METHYLTRANSFERASE INHIBITOR; EPIMUTAGEN; GUANINE; MUTAGENIC AGENT; OLIGODEOXYNUCLEOTIDE; PHOSPHORAMIDOUS ACID; THREONINE; UNCLASSIFIED DRUG; 2' DEOXYRIBOGUANYLUREA; 2'-DEOXYRIBOGUANYLUREA; 5 AZA 2' DEOXYCYTIDINE; DEOXYRIBOSE; DNA (CYTOSINE 5 ) METHYLTRANSFERASE 1; DNA (CYTOSINE 5) METHYLTRANSFERASE; DNA (CYTOSINE-5-)-METHYLTRANSFERASE 1; DNA MODIFICATION METHYLASE ECORII; DRUG DERIVATIVE; ENZYME INHIBITOR; GUANIDINE DERIVATIVE; OLIGODEOXYRIBONUCLEOTIDE;

ARTICLE; BASE PAIRING; CHEMICAL STRUCTURE; DEMETHYLATION; ESCHERICHIA COLI; HUMAN; HUMAN CELL; MALE; MICROFLUIDICS; MUTAGENESIS; MUTATIONAL ANALYSIS; NONHUMAN; NUCLEIC ACID AMPLIFICATION; NUCLEIC ACID BASE SUBSTITUTION; PHASE TRANSITION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SYNTHESIS; CHEMISTRY; CHROMOSOME FRAGILE SITE; DRUG ANTAGONISM; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; TUMOR CELL LINE;

BACTERIA (MICROORGANISMS);

AZACITIDINE; BASE SEQUENCE; CELL LINE, TUMOR; CHROMOSOME FRAGILE SITES; DEOXYRIBOSE; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; DNA MODIFICATION METHYLASES; DNA-CYTOSINE METHYLASES; ENZYME INHIBITORS; GUANIDINES; HUMANS; MOLECULAR SEQUENCE DATA; MUTAGENESIS; MUTAGENS; OLIGODEOXYRIBONUCLEOTIDES;

EID: 84868136467     PISSN: 03051048     EISSN: 13624962     Source Type: Journal    
DOI: 10.1093/nar/gks706     Document Type: Article

References (50)

1. Cupples, C.G. and Miller, J.H. (1989) A set of lacZ mutations in Escherichia coli that allow rapid detection of each of the six base substitutions. Proc. Natl Acad. Sci. USA, 86, 5345-5349. (Pubitemid 19185549)
2. Fucik, V., Zadrazil, S., Sormova, Z. and F.S. (1965) Mutagenic effects of 5-azacytidine in bacteria. Collect. Czech. Chem. Commun., 30, 2883-2886.
3. Bhagwat, A.S. and Roberts, R.J. (1987) Genetic analysis of the 5-azacytidine sensitivity of Escherichia coli K-12. J. Bacteriol., 169, 1537-1546. (Pubitemid 17063481)
4. Call, K.M., Jensen, J.C., Liber, H.L. and Thilly, W.G. (1986) Studies of mutagenicity and clastogenicity of 5-azacytidine in human lymphoblasts and Salmonella typhimurium. Mutat. Res., 160, 249-257. (Pubitemid 16076288)
5. Carr, B.I., Reilly, J.G., Smith, S.S., Winberg, C. and Riggs, A. (1984) The tumorigenicity of 5-azacytidine in the male Fischer rat. Carcinogenesis, 5, 1583-1590. (Pubitemid 15127023)
6. Harris, M. (1982) Induction of thymidine kinase in enzyme-deficient Chinese hamster cells. Cell, 29, 483-492. (Pubitemid 12024839)
7. Schmid, M., Haaf, T. and Grunert, D. (1984) 5-Azacytidine-induced undercondensations in human chromosomes. Hum. Genet., 67, 257-263. (Pubitemid 15195884)
8. Hori, T.A. (1983) Induction of chromosome decondensation, sister-chromatid exchanges and endoreduplications by 5-azacytidine, an inhibitor of DNA methylation. Mutat. Res., 121, 47-52. (Pubitemid 13032523)
9. Komashko, V.M. and Farnham, P.J. (2010) 5-azacytidine treatment reorganizes genomic histone modification patterns. Epigenetics, 5, 229-240.
10. Jackson-Grusby, L., Laird, P.W., Magge, S.N., Moeller, B.J. and Jaenisch, R. (1997) Mutagenicity of 5-aza-20-deoxycytidine is mediated by the mammalian DNA methyltransferase. Proc. Natl Acad. Sci. USA, 94, 4681-4685.
11. Juttermann, R., Li, E. and Jaenisch, R. (1994) Toxicity of 5-aza-20-deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation. Proc. Natl Acad. Sci. USA, 91, 11797-11801.
12. Ghoshal, K., Datta, J., Majumder, S., Bai, S., Kutay, H., Motiwala, T. and Jacob, S.T. (2005) 5-Aza-deoxycytidine induces selective degradation of DNA methyltransferase 1 by a proteasomal pathway that requires the KEN box, bromo-adjacent homology domain, and nuclear localization signal. Mol. Cell Biol., 25, 4727-4741. (Pubitemid 40705775)
13. Rogstad, D.K., Herring, J.L., Theruvathu, J.A., Burdzy, A., Perry, C.C., Neidigh, J.W. and Sowers, L.C. (2009) Chemical decomposition of 5-aza-20-deoxycytidine (Decitabine): kinetic analyses and identification of products by NMR, HPLC, and mass spectrometry. Chem. Res. Toxicol., 22, 1194-1204.
14. Jones, P.A. and Taylor, S.M. (1980) Cellular differentiation, cytidine analogs and DNA methylation. Cell, 20, 85-93. (Pubitemid 10117303)
15. Christman, J.K., Schneiderman, N. and Acs, G. (1985) Formation of highly stable complexes between 5-azacytosine-substituted DNA and specific non-histone nuclear proteins. Implications for 5-azacytidine-mediated effects on DNA methylation and gene expression. J. Biol. Chem., 260, 4059-4068. (Pubitemid 15096474)
16. Friedman, S. (1982) Bactericidal effect of 5-azacytidine on Escherichia coli carrying EcoRII restriction-modification enzymes. J. Bacteriol., 151, 262-268. (Pubitemid 12022332)
17. Pfleiderer, W. (2007) Universal 2-(4-nitrophenyl)ethyl and 2-(4-nitrophenyl)ethoxycarbonyl protecting groups for nucleosides and nucleotides. Curr. Protoc. Nucleic Acid Chem., Chapter 2, Unit 2 13.
18. Guimil Garcia, R., Brank, A.S., Christman, J.K., Marquez, V.E. and Eritja, R. (2001) Synthesis of oligonucleotide inhibitors of DNA (Cytosine-C5) methyltransferase containing 5-azacytosine residues at specific sites. Antisense Nucleic Acid Drug Dev., 11, 369-378. (Pubitemid 34106802)
19. Liu, M.C., Luo, M.Z., Mozdziesz, D.E., Lin, T.S., Dutschman, G.E., Cheng, Y.C. and Sartorelli, A.C. (1999) Synthesis of 20-methylene-substituted 5-azapyrimidine, 6-azapyrimidine, and 3-deazaguanine nucleoside analogues as potential antitumor/antiviral agents. Nucleosides Nucleotides, 18, 55-72. (Pubitemid 29093201)
20. Diaz, A.R., Eritjaa, R. and Garcia, R.G. (1997) Synthesis of oligodeoxynucleotides containing 2-substituted guanine derivatives using 2-fluoro-20-deoxyinosine as common nucleoside precursor. Nucleosides, Nucleotides Nucleic Acids, 16, 2035-2051.
21. Alul, R.H., Singman, C.N., Zhang, G.R. and Letsinger, R.L. (1991) Oxalyl-CPG: a labile support for synthesis of sensitive oligonucleotide derivatives. Nucleic Acids Res., 19, 1527-1532. (Pubitemid 21913247)
22. Pon, R.T. and Yu, S. (1997) Hydroquinone-O, O0-diacetic acid ('Q-linker') as a replacement for succinyl and oxalyl linker arms in solid phase oligonucleotide synthesis. Nucleic Acids Res., 25, 3629-3635. (Pubitemid 27390181)
23. Dignam, J.D., Lebovitz, R.M. and Roeder, R.G. (1983) Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucleic Acids Res., 11, 1475-1489.
24. Okuwaki, M. and Verreault, A. (2004) Maintenance DNA methylation of nucleosome core particles. J. Biol. Chem., 279, 2904-2912. (Pubitemid 38114282)
25. Kho, M.R., Baker, D.J., Laayoun, A. and Smith, S.S. (1998) Stalling of human DNA (cytosine-5) methyltransferase at single-strand conformers from a site of dynamic mutation. J. Mol. Biol., 275, 67-79. (Pubitemid 28022388)
26. Friedman, S. (1985) The irreversible binding of azacytosine-containing DNA fragments to bacterial DNA(cytosine-5)methyltransferases. J. Biol. Chem., 260, 5698-5705. (Pubitemid 15001131)
27. Clark, J., Shevchuk, T., Swiderski, P.M., Dabur, R., Crocitto, L.E., Buryanov, Y.I. and Smith, S.S. (2003) Mobility-shift analysis with microfluidics chips. Biotechniques, 35, 548-554. (Pubitemid 37108256)
28. Munson, K., Clark, J., Lamparska-Kupsik, K. and Smith, S.S. (2007) Recovery of bisulfite-converted genomic sequences in the methylation-sensitive QPCR. Nucleic Acids Res., 35, 2893-2903. (Pubitemid 47073628)
29. Clark, J. and Smith, S.S. (2008) Secondary structure at a hot spot for DNA methylation in DNA from human breast cancers. Cancer Genomics Proteomics, 5, 241-251.
30. Shevchuk, T., Kretzner, L., Munson, K., Axume, J., Clark, J., Dyachenko, O.V., Caudill, M., Buryanov, Y. and Smith, S.S. (2005) Transgene-induced CCWGG methylation does not alter CG methylation patterning in human kidney cells. Nucleic Acids Res., 33, 6124-6136. (Pubitemid 41742551)
31. Chaplin, M.F. and Bucke, C. (1990) Enzyme Technology. Cambridge University Press, Cambridge, UK.
32. Friedman, S. (1979) The effect of 5-azacytidine on E. coli DNA methylase. Biochem. Biophys. Res. Commun., 89, 1328-1333. (Pubitemid 9256475)
33. Lin, K.T., Momparler, R.L. and Rivard, G.E. (1981) High-performance liquid chromatographic analysis of chemical stability of 5-aza-20-deoxycytidine. J. Pharm. Sci., 70, 1228-1232. (Pubitemid 12166545)
34. Chan, K.K., Giannini, D.D., Staroscik, J.A. and Sadee, W. (1979) 5-Azacytidine hydrolysis kinetics measured by high-pressure liquid chromatography and 13C-NMR spectroscopy. J. Pharm. Sci., 68, 807-812. (Pubitemid 9224244)
35. Clark, J., Shevchuk, T., Kho, M.R. and Smith, S.S. (2003) Methods for the design and analysis of oligodeoxynucleotide-based DNA (cytosine-5) methyltransferase inhibitors. Anal. Biochem., 321, 50-64. (Pubitemid 37083267)
36. Cheng, J.C., Yoo, C.B., Weisenberger, D.J., Chuang, J., Wozniak, C., Liang, G., Marquez, V.E., Greer, S., Orntoft, T.F., Thykjaer, T. et al. (2004) Preferential response of cancer cells to zebularine. Cancer Cell, 6, 151-158. (Pubitemid 39485687)
37. Zhou, L., Cheng, X., Connolly, B.A., Dickman, M.J., Hurd, P.J. and Hornby, D.P. (2002) Zebularine: a novel DNA methylation inhibitor that forms a covalent complex with DNA methyltransferases. J. Mol. Biol., 321, 591-599. (Pubitemid 36124798)
38. Goodman, M.F. (1997) Hydrogen bonding revisited: geometric selection as a principal determinant of DNA replication fidelity. Proc. Natl Acad. Sci. USA, 94, 10493-10495. (Pubitemid 27430760)
39. Ehrlich, M., Jackson, K. and Weemaes, C. (2006) Immunodeficiency, centromeric region instability, facial anomalies syndrome (ICF). Orphanet. J. Rare Dis., 1, 2.
40. Paz, M.F., Fraga, M.F., Avila, S., Guo, M., Pollan, M., Herman, J.G. and Esteller, M. (2003) A systematic profile of DNA methylation in human cancer cell lines. Cancer Res., 63, 1114-1121. (Pubitemid 36278446)
41. Ibragimova, I., Ibanez de Caceres, I., Hoffman, A.M., Potapova, A., Dulaimi, E., Al-Saleem, T., Hudes, G.R., Ochs, M.F. and Cairns, P. (2010) Global reactivation of epigenetically silenced genes in prostate cancer. Cancer Prev. Res., 3, 1084-1092.
42. Beisler, J.A., Abbasi, M.M., Kelley, J.A. and Driscoll, J.S. (1977) Synthesis and antitumor activity of dihydro-5-azacytidine, a hydrolytically stable analogue of 5-azacytidine. J. Med. Chem., 20, 806-812. (Pubitemid 8096810)
43. Bouzon, M. and Marliere, P. (1997) Human deoxycytidine kinase as a conditional mutator in Escherichia coli. C R Acad. Sci. III, 320, 427-434. (Pubitemid 27290361)
44. Momparler, R.L., Bouffard, D.Y., Momparler, L.F., Dionne, J., Belanger, K. and Ayoub, J. (1997) Pilot phase I-II study on 5-aza-20-deoxycytidine (Decitabine) in patients with metastatic lung cancer. Anticancer Drugs, 8, 358-368. (Pubitemid 27204954)
45. Juergens, R.A., Wrangle, J., Vendetti, F.P., Murphy, S.C., Zhao, M., Coleman, B., Sebree, R., Rodgers, K., Hooker, C.M., Franco, N. et al. (2011) Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer. Cancer Discov., 1, 598-607.
46. Smith, S.S. and Crocitto, L. (1999) DNA methylation in eukaryotic chromosome stability revisited: DNA methyltransferase in the management of DNA conformation space. Mol. Carcinog., 26, 1-9. (Pubitemid 29420180)
47. Smith, S.S. (2000) Gilbert0s conjecture: the search for DNA (cytosine-5) demethylases and the emergence of new functions for eukaryotic DNA (cytosine-5) methyltransferases. J. Mol. Biol., 302, 1-7.
48. Kantarjian, H., Issa, J.P., Rosenfeld, C.S., Bennett, J.M., Albitar, M., DiPersio, J., Klimek, V., Slack, J., de Castro, C., Ravandi, F. et al. (2006) Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer, 106, 1794-1803.
49. Alva, A.S., Hahn, N.M., Aparicio, A.M., Singal, R., Yellapragada, S. and Sonpavde, G. (2011) Hypomethylating agents for urologic cancers. Future Oncol., 7, 447-463.
50. Hatoum, H.T., Lin, S.J., Buchner, D. and Kim, E. (2011) Use of hypomethylating agents and associated care in patients with myelodysplastic syndromes: a claims database study. Curr. Med. Res. Opin., 27, 1255-1262.